Published in PLoS One on December 11, 2013
Role of Pharmacovigilance in India: An overview. Online J Public Health Inform (2015) 0.90
The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol (2016) 0.86
Targets of drugs are generally, and targets of drugs having side effects are specifically good spreaders of human interactome perturbations. Sci Rep (2015) 0.78
Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol (2010) 39.63
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 32.05
DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res (2007) 13.94
Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med (2010) 4.32
Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med (2012) 3.26
The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther (2011) 2.93
Developing the Sentinel System--a national resource for evidence development. N Engl J Med (2011) 2.93
Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol (1999) 2.78
The new Sentinel Network--improving the evidence of medical-product safety. N Engl J Med (2009) 2.73
The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf (2012) 2.70
Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf (2010) 2.57
Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf (2012) 2.41
Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol (2004) 2.32
Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf (2010) 2.29
Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol (2008) 2.24
Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf (2009) 1.96
Data mining applications in healthcare. J Healthc Inf Manag (2005) 1.84
In silico research in the era of cloud computing. Nat Biotechnol (2010) 1.81
Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol (1998) 1.78
The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf (2012) 1.73
HCLS 2.0/3.0: health care and life sciences data mashup using Web 2.0/3.0. J Biomed Inform (2008) 1.63
Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: application to rhabdomyolysis. J Am Med Inform Assoc (2011) 1.44
Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf (2012) 1.36
Signal selection and follow-up in pharmacovigilance. Drug Saf (2002) 1.32
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
The EU-ADR project: preliminary results and perspective. Stud Health Technol Inform (2009) 1.15
Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc (2012) 1.09
EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform (2011) 1.06
Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf (2011) 1.04
Automatic filtering and substantiation of drug safety signals. PLoS Comput Biol (2012) 0.96
The EU-ADR Web Platform: delivering advanced pharmacovigilance tools. Pharmacoepidemiol Drug Saf (2012) 0.95
Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data. Pharmacoepidemiol Drug Saf (2012) 0.94
Highlights of drug package inserts and the website DailyMed: the need for further improvement in package inserts to help busy prescribers. J Clin Psychopharmacol (2011) 0.89
Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system. PLoS One (2013) 0.88
Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol (2002) 0.88
A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project. Stud Health Technol Inform (2009) 0.87
Regulatory innovation in postmarketing risk assessment and management. Clin Pharmacol Ther (2012) 0.86
COEUS: "semantic web in a box" for biomedical applications. J Biomed Semantics (2012) 0.86
Signal detection in pharmacovigilance: empirical evaluation of data mining tools. Pharmacoepidemiol Drug Saf (2005) 0.84
A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006. Pharmacoepidemiol Drug Saf (2011) 0.82
Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National pharmacovigilance Centres. Drug Saf (2003) 0.81
The RADAR project and the FDA. JAMA (2005) 0.78